Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Exits Indian Industry Group: Fault Lines Showing?

Executive Summary

Abbott’s unexpected decision to move out of the Organization of Pharmaceutical Producers of India (OPPI), the premier multinational industry body in India, has provided enough grist to the rumor mill to work overtime.  Experts tell Scrip where the divisive issues may lie.

You may also be interested in...



India's Device Price Cap Storm Rages On: New Stent Cap And Spotlight On Catheter Trade Margins

India’s medical device pricing storm looks unlikely to abate any time soon, with another round of price caps on stents being enforced. The spotlight is also shining on the sharp variances in trade margins for catheters in the country.

Indian Firms Push For Favorable USTR IPR Review

It’s that time of the year when Indian and US firms lock horns around all things IPR [intellectual property rights] ahead of the USTR’s annual Special 301 report. Indian pharma firms want India off the USTR’s Priority Watch List, while PhRMA says it remains concerned about the challenging policy environment and weak patent enforcement in India.

Asia Deal Watch: Rhizen Licenses Chinese Rights For PI3K Inhibitor To Curon

Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.

Topics

UsernamePublicRestriction

Register

ID014775

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel